This site uses cookies. To find out more, see our Cookies Policy

Senior Director, Global Oncology Biomarker and Cdx Strategy Lead in Bernards, NJ at DSI

Date Posted: 2/2/2019

Job Snapshot

Job Description

About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science, we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. Our powerful research engines include two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA.

Job Summary:

The Senior Director, Global Oncology Biomarkers and Companion diagnostic Strategy Lead is a high profile marketing role and a key member of the Global Oncology Marketing team reporting directly to the Vice President Head of Global Oncology Marketing of Daiichi Sankyo.

The Biomarker & Cdx lead will drive strategies and marketing efforts within biomarker & diagnostic covering the entire portfolio of Daiichi Sankyo CancerEnterprise from early assets to ready-to-launch assets.

The BM/Cdx lead will be fully responsible for developing and implementing both marketing strategy and tactical programs for Biomarkers and Cdx. The lead will work closely with R&D to co-develop Companion diagnostic strategic elements in the development and pivotal programs by providing marketing/commercial perspective; will support business development team to select Cdx partner; and finally will lead the development of a marketing global launch strategy to drive successful commercial execution of companion diagnostics in markets with support from R&D CDx lead and in collaboration with the Cdx partner. This position requires a solid understanding of the role of Biomarkers and CDx in oncology from a marketing perspective as a driver of value in the commercialization of any asset launched with a CDx driven label.

This position will work with many stakeholders including but not limited to Brand Marketing Lead, New Product Planning Lead, Research & Development, Medical Affairs, Regulatory, Market Access and Pricing, Business Development as well as external partners such as the Cdx partner. This position requires an inclusive collaborative leadership skill associated with strong business acumen. Interactions with regional leadership and operating teams in key markets (US, Europe, Japan and other key markets) will be critical for the success of the Biomarker & Cdx marketing strategy. Inputs from regions during the development stage, the strategy development as well as business reviews with them are expected.

Finally the BM&Cdx lead will have to deal with complex situations in a highly competitive and changing environment and will be viewed as the Marketing SME in this topic within the organization making this position highly visible.

  • Provide commercial insight to R&D and R&D Cdx Lead, Business development and Regulatory on the biomarker elements embedded in the development strategy of any oncology asset of Daiichi Sankyo. The most important contribution will be for the decision regarding of pivotal programs and will include alignment with regional leadership.
  • Develop a “go to market” strategy to support the Cdx launch in collaboration with key stakeholders of the global team (Marketing, Medical Affairs and Market Access leads) and with the external partners - mainly the Cdx company.
  • In collaboration with regions and other functions, develop a launch tactical plan that will address all dimensions (Sample tissue flow, stakeholder engagement, message development, competitive differentiation) for a successful launch and readiness with a flawless execution of pre-launch and launch activities including performance tracking and analytic plan on KPI.
  • In collaboration with external partners, mainly the Cdx company, to obtain full alignment between the two organizations and create synergies between the two from the execution of respective tactical plans.
  • Monitor the market evolution in terms of new technology of biomarkers and emerging companies in this area of Cdx in commercialization efforts and/ or in the translational research efforts of the company.

Ability to travel approximately 25% either global or domestic travel

Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.

  • Qualified candidates must have a Bachelor’s degree from an accredited college or university; MBA or advanced degree (eg Phd, Pharm MD, MD) preferred.
  • 12 years+ of experience in Pharma in various positions including managerial position and global position
  • Oncology experience is required
  • 5-10 years of marketing (Global and in-market) experience in oncology ideally on asset approved with a Cdx indication will be highly regarded. Experience should include director level managing an entire asset, or a major indication for a multi-billion asset
  • 2+ years’ experience focusing on Biomarker and Cdx in oncology or non-oncology is a plus
  • Experience working at a Cdx company (Oncology specific) without Pharmaceutical marketing experience will be considered
  • Candidates with R&D experience who have being highly involved in integrating Biomarker & Cdx elements in late stage asset (pivotal program) and being a core member of the Global Brand team in the launch readiness will be also considered

Daiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected veteran status, age, or any other characteristic protected by law.